Confluent starts pivotal anti-adhesion US trial:
This article was originally published in Clinica
Executive Summary
Confluent Surgical has begun a pivotal trial in the US to assess its sprayable gel as a means of preventing pelvic adhesions following laparoscopic surgery in women. Early studies have shown that the product - SprayGel - remains in place as a barrier for five to seven days, the period when adhesions normally form, says the Waltham, Massachusetts firm. The company notes that adhesions are estimated to affect over two million women and men in the US, where the potential market for abdominopelvic adhesion management is $400-$500m. SprayGel is currently available in Europe and Australia.
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.